Cell Lines for SARS-CoV-2 Research

Protocol · Cell lines · Virology · Susceptibility · Vaccine production · Hybridomas

Published 2026 · Last updated 2026-10-28 · Hailu Zhou

When SARS-CoV-2 emerged in late 2019, the first practical question for most laboratories was not which assay to run but which cells to run it in. A virus that enters through the ACE2 receptor and is primed by TMPRSS2 will only replicate efficiently in cells that express both, and the permissiveness of a given line turned out to vary enormously — between organs, between lines from the same organ, and between subclones of the same line. The Cellosaurus knowledge base maintains a curated catalogue of the cell lines relevant to this work, organised into five practical categories: lines that support viral growth, engineered lines built for entry and replication studies, lines documented as poorly permissive, lines used in vaccine manufacturing, and hybridomas secreting antibodies against viral proteins. This article works through those five categories, with the caveat that the field moved fast and the underlying annotations are the authoritative record.

Why cell-line choice matters so much for this virus

SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as its entry receptor, and the spike protein must be proteolytically cleaved at the S2′ site by a host protease — principally TMPRSS2 at the plasma membrane, or cathepsin L in the endosomal route — before membrane fusion can occur. The consequences for cell culture are direct. A line that expresses ACE2 but not TMPRSS2 can still be infected, but the virus is forced into the endosomal pathway; adding exogenous trypsin or overexpressing TMPRSS2 restores the plasma-membrane route and can change the resulting cytopathic phenotype. A line that expresses neither is effectively resistant no matter how much virus is added.

This is why permissiveness is a property of the specific cell, not of the species or organ. It also explains why the two most widely used lines in the field — Vero and its derivative Vero E6 — behave the way they do: both are interferon-defective African green monkey kidney lines, which makes them highly permissive and gives large, easily scored plaques, but the same defect means they are a poor model for interferon biology. Conversely, human respiratory lines such as Calu-3 recapitulate the airway context far better but grow more slowly and yield lower titres.

A. Cell lines that can be used to grow SARS-CoV-2

The lines with documented susceptibility span kidney, intestinal, respiratory and hepatocyte-like origins. Cellosaurus identifiers are given so that the exact authenticated line can be retrieved rather than an ambiguous name.

Two practical points. First, permissiveness is usually reported as a titre or as cytopathic effect at a given multiplicity of infection, and both are assay-dependent; a line described as "poorly permissive" in one study may be workable with a different inoculum or a longer incubation. Second, the species of the line matters for interpreting the result: a monkey kidney line tells you the virus can replicate in a kidney cell, not that it replicates in human airway epithelium.

B. Engineered lines for entry and replication studies

Because natural permissiveness varies so much, a large secondary toolbox was built by engineering susceptibility into convenient host lines. The most common design is overexpression of human ACE2, sometimes together with TMPRSS2, in a line that is otherwise easy to transfect or transduce. These lines make it possible to compare entry of different variants, to test entry inhibitors and neutralising antibodies with a clean readout, and to run pseudovirus assays at biosafety level 2.

Two families dominate. The first is ACE2-overexpressing derivatives of standard laboratory lines, typically HEK293T or A549, used for pseudotyped lentivirus or VSV entry assays. The second is lines expressing individual viral proteins — nucleocapsid, the non-structural proteins, or the spike protein itself — used to study protein function, assembly or the cellular response to a single viral component without live-virus infection. Cellosaurus groups these under a dedicated "SARS-CoV-2 research cell line" collection precisely because the naming is otherwise inconsistent across labs.

A design caution worth stating plainly: a pseudovirus entry assay measures entry and nothing else. It cannot report on replication, assembly, egress or innate immune evasion, and apparent differences between variants in such an assay do not automatically translate into fitness differences in a real infection. Engineered lines are a reductionist tool, and they should be paired with a permissive line and live virus when the question is about the virus rather than about the receptor.

C. Lines shown not to support efficient growth

Negative results are as useful as positive ones here, and the catalogue records lines that failed to support productive infection. These are typically cells that lack sufficient ACE2, that lack a usable protease, or that mount a strong interferon response. The practical value is twofold: they serve as negative controls that demonstrate the specificity of an entry assay, and they prevent a laboratory from spending weeks optimising a system that was never going to work.

It is worth being precise about what "not suitable" means. Very few lines are absolutely refractory at any inoculum; most are simply inefficient, producing low or undetectable titres under standard conditions. A line in this category may still be infectious at a high multiplicity, may support a single round of replication without spread, or may become permissive after ACE2 transduction — which is exactly how several of the engineered lines in category B were constructed. If your question requires a resistant background, verify resistance in your own hands rather than relying on a catalogue annotation made under different conditions.

D. Cell lines used in COVID-19 vaccine production

This is the category that attracted the most public attention and the most misunderstanding. Several vaccine platforms depend on a cell line at some manufacturing stage: viral-vector vaccines grow the vector in a producer line, inactivated-virus vaccines grow the virus itself in a permissive line, and recombinant subunit vaccines express the spike protein in an expression host. The mapping below follows the Cellosaurus catalogue and the corresponding vaccine trials.

The point that is routinely lost in public discussion: vaccines do not contain cells, and they do not contain the cell line's DNA in any functional form. The cell line is a manufacturing substrate, in the same sense that a stainless-steel bioreactor is a manufacturing vessel. It is removed during purification, and any residual host-cell DNA is present at trace levels that regulators assess explicitly. The fetal-cell-line question is a real ethical debate with a legitimate history, but it is a debate about the origin of a manufacturing substrate, not about what is injected.

From a technical standpoint, each platform imposes its own constraints. Vero is a WHO-recommended continuous substrate for viral vaccines and scales in adherent or microcarrier culture, but it is interferon-defective and must be carefully screened for adventitious agents. HEK293-based vector production gives high yields in suspension but requires attention to vector genome integrity and replication-competent adenovirus. Sf9/baculovirus gives high antigen yields but produces a different glycosylation pattern from mammalian cells, which matters for a spike antigen intended to mimic the native trimer.

E. Hybridomas producing antibodies against viral proteins

The final category is the reagent side of the field. Hybridomas raised against the spike protein (S) supply the neutralising and detection antibodies used in ELISA, western blot, flow cytometry, immunohistochemistry and neutralisation assays; hybridomas raised against the nucleoprotein (N) supply the backbone of most antigen-detection assays, because N is abundantly expressed and well conserved. Cellosaurus annotates these by target protein, with UniProt accessions P0DTC2 for spike and P0DTC9 for nucleoprotein, so that a reagent can be tied to a defined antigen rather than a clone name alone.

Two practical notes for anyone building assays with these reagents. First, epitope matter more than clone name: an anti-S antibody binding the receptor-binding domain will behave very differently from one binding the S2 fusion machinery, and variant escape mutations fall disproportionately in the RBD. Second, anti-N reagents are more tolerant of variant change but cannot distinguish vaccination from infection in a serology assay unless paired with an anti-S readout — the basis of the standard "S-positive, N-negative" interpretation for vaccine-induced immunity.

Putting the catalogue to use

A reasonable decision sequence for a new project runs as follows. Define whether the question concerns entry, replication, pathogenesis or immunity. For entry, use an engineered ACE2/TMPRSS2 line with a pseudovirus, and confirm key findings with live virus in Vero E6. For replication and antiviral testing, use Vero E6 for throughput and Calu-3 for physiological relevance, and report titres rather than only cytopathic effect. For pathogenesis and tropism, prefer differentiated human airway or intestinal models, and treat monkey kidney lines as a permissive substrate rather than a disease model. For vaccine or antibody work, select the substrate the platform actually uses, and characterise the reagent's epitope before relying on it across variants.

Whatever the design, three controls should be non-negotiable: an authenticated line identity (STR or the bank's certificate), a documented passage number, and a negative-control line that is not permissive. The catalogue tells you which lines are plausible; only your own hands tell you whether the system works.

References

  1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
  2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
  3. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi:10.1038/s41586-020-2180-5
  4. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi:10.1126/science.abb2507
  5. Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429–446.e14. doi:10.1016/j.cell.2020.05.042
  6. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. doi:10.1016/j.cell.2020.04.004
  7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
  8. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi:10.1016/S0140-6736(20)31866-3
  9. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578–582. doi:10.1038/s41586-020-2608-y
  10. Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25–38. doi:10.7171/jbt.18-2902-002
  11. Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132(11):2510–2519. doi:10.1002/ijc.27931